
Pipeline
We are working to deliver best-in-class pan-variant TKIs to fight cancer.
Our pipeline focuses on developing next-generation TKIs that address the key limitation of drug resistance.
Program/Target
Indication
Stage
Discovery
IND-Enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights

We are targeting cancers driven by clinically validated driver oncogenes, where current therapies are limited by the development of resistance.
LEARN ABOUT OUR DISEASE FOCUS